(Q36708370)

15 August 2017

1 reference

title

Severe psoriasis treated with a new macrolide: everolimus (English)

1 reference

15 August 2017

Frigerio E

1

1 reference

15 August 2017

Colombo MD

2

1 reference

15 August 2017

Franchi C

3

1 reference

15 August 2017

Altomare A

4

1 reference

15 August 2017

Garutti C

5

1 reference

15 August 2017

Altomare GF

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

British Journal of Dermatology

15 August 2017

published in

1 reference

15 August 2017

volume

156

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

372-374

1 reference

Inflammatory skin diseases, T cells, and immune surveillance

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07602.X

Review of the proliferation inhibitor everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07602.X

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07602.X

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07602.X

Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07602.X

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07602.X

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07602.X

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07602.X

10.1111/J.1365-2133.2006.07602.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference